A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure

NCT00510913 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Graft Rejection
Kidney Transplantation

Interventions

DRUG: tacrolimus

Sponsor

Astellas Pharma Inc